[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.161.175.236. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Letters
November 14, 2012

Treatment With Silymarin for Hepatitis C Virus—Reply

Author Affiliations

Author Affiliations: Division of Gastroenterology and Hepatology, University of North Carolina, Chapel Hill (Dr Fried; mfried@med.unc.edu); Division of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, Chapel Hill, North Carolina (Dr Hawke); and Division of Gastroenterology and Hepatology, University of Pennsylvania, Philadelphia (Dr Reddy).

JAMA. 2012;308(18):1856-1857. doi:10.1001/jama.2012.13744

In Reply: The presence of conflicting data regarding the efficacy of silymarin was a prime motivator for conducting detailed phase 1 and phase 2 clinical trials of oral silymarin in a well-characterized population with chronic hepatitis C.13 We agree that the reports of intravenous silibinin succinate for HCV are intriguing and deserve further inquiry; however, they are not analogous to studies of the oral formulation.4

First Page Preview View Large
First page PDF preview
First page PDF preview
×